<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175901</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2014006</org_study_id>
    <nct_id>NCT02175901</nct_id>
  </id_info>
  <brief_title>Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication</brief_title>
  <official_title>Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No trial has examined the the efficacy of amoxicillin and metronidazole based quadruple&#xD;
      therapy for Helicobacter pylori treatment. The study aims to compare the effectiveness and&#xD;
      safety of 14-day amoxicillin-/metronidazole-based quadruple regiment and classical quadruple&#xD;
      regiment for Helicobacter pylori eradication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori is the most successful human pathogen infecting an estimated 50% of the&#xD;
      global population. It is a common and potentially curable cause of dyspepsia and peptic ulcer&#xD;
      disease. Eradication in patients with peptic ulcer or even functional or non-investigated&#xD;
      dyspepsia is a cost effective approach.&#xD;
&#xD;
      Most Consensus Conferences and Clinical Guidelines recommend the prescription of a triple&#xD;
      therapy including a proton pump inhibitor (PPI) and clarithromycin with either amoxicillin or&#xD;
      metronidazole, as first-line treatment. However, the effectiveness of these triple-therapy&#xD;
      regimens seems to have diminished over time, largely as a result of emerging resistance of&#xD;
      the organism to clarithromycin. Due to the low efficacy achieved with these treatments, they&#xD;
      have been deemed as unethical comparators in clinical trials. As antimicrobial resistance&#xD;
      becomes more prevalent worldwide, treatment failure rates are likely to continue increasing,&#xD;
      suggesting that new regimens for H pylori eradication must be sought.&#xD;
&#xD;
      Bismuth-containing quadruple therapies have been used widely in H. pylori therapy with many&#xD;
      permutations of doses and durations and with variable results. Classical bismuth-based&#xD;
      quadruple therapy containing a PPI, bismuth, tetracycline and metronidazole has been&#xD;
      recommended as the first-line treatment by the Maastricht IV Consensus Conference report and&#xD;
      H. pylori Study Group of Chinese Society of Gastroenterology. But this regiment has high rate&#xD;
      of side effects because of tetracycline. Standard triple therapy-based, bismuth-containing&#xD;
      quadruple Therapy is also an alternative. Though addition bismuth and prolonging treatment&#xD;
      duration can overcome H. pylori resistance to clarithromycin, its use as a first-line&#xD;
      treatment is limited in areas of high clarithromycin resistance.&#xD;
&#xD;
      Amoxicillin has low resistance rate as well as low percentage of side effects. The&#xD;
      combination of amoxicillin and metronidazole in bismuth-containing quadruple therapy may be a&#xD;
      better choice, which can avoid clarithromycin resistance and reduce side effects. Therefore,&#xD;
      we will do a randomized trial to compare the eradication rate of 14-day amoxicillin and&#xD;
      metronidazole based bismuth-containing quadruple therapy with amoxicillin and clarithromycin&#xD;
      based quadruple therapy for Helicobacter pylori infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori</measure>
    <time_frame>2 months</time_frame>
    <description>Access eradication rate of H. pylori by intention to treat (ITT) and per-protocol (PP) analysis in each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects of each treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Score side effects as mild, moderate or severe according to their influence on daily activities</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal inhibitory concentrations (MIC) of antibiotics against each helicobacter pylori clinical isolate</measure>
    <time_frame>2 months</time_frame>
    <description>Determine MIC of amoxicillin, clarithromycin, and metronidazole by the twofold agar dilution method.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>antisecretory drug of each quadruple therapy</description>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <other_name>proton pump inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Potassium Citrate</intervention_name>
    <description>one component of each quadruple therapy</description>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <other_name>Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>antibiotic of each quadruple therapy</description>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>antibiotic of the amoxicillin/metronidazole-based quadruple therapy</description>
    <arm_group_label>Amoxicillin/metronidazole</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>antibiotic of the amoxicillin/clarithromycin-based quadruple therapy</description>
    <arm_group_label>Amoxicillin/clarithromycin</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with non-investigated/functional dyspepsia or scarred peptic ulcer with&#xD;
             indication of H pylori eradication treatment&#xD;
&#xD;
          -  Ability and willingness to participate in the study and to sign and give informed&#xD;
             consent&#xD;
&#xD;
          -  confirmed H pylori infection by at least one of the following methods: C13-urea breath&#xD;
             test, histology, rapid urease test or bacterial culture.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with peptic ulcer&#xD;
&#xD;
          -  previous H. pylori eradication therapy&#xD;
&#xD;
          -  Age below 18 years&#xD;
&#xD;
          -  major systemic diseases&#xD;
&#xD;
          -  previous gastric surgery&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  allergy to any of the study drugs&#xD;
&#xD;
          -  receipt of anti-secretory therapy, antibiotics or bismuth salts 4 weeks prior to&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Renji Hospital, Shanghai Jiao-Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.</citation>
    <PMID>22491499</PMID>
  </reference>
  <reference>
    <citation>Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.</citation>
    <PMID>20557366</PMID>
  </reference>
  <reference>
    <citation>Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1134-40. doi: 10.1097/MEG.0b013e3283633b57. Review.</citation>
    <PMID>23778309</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hong Lu, MD</investigator_full_name>
    <investigator_title>Professor of GI Division</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori eradication</keyword>
  <keyword>antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

